Anixa Biosciences CEO Featured on Smart Money Circle Interview Highlighting Advances in Cancer Immunotherapy Programs

Anixa Biosciences (NASDAQ: ANIX) said its CEO Dr. Amit Kumar discussed the company’s advancing immunotherapy pipeline on Smart Money Circle on April 6, 2026.

Rhea-AI Summary

Anixa Biosciences (NASDAQ: ANIX) said its CEO Dr. Amit Kumar discussed the company’s advancing immunotherapy pipeline on Smart Money Circle on April 6, 2026. Key clinical updates: the breast cancer vaccine completed Phase 1 meeting primary endpoints with protocol-defined immune responses in 74% of participants, and the ovarian CAR-T therapy lira-cel is showing positive survival data in an ongoing Phase 1 trial.

The interview highlights clinical progress across both programs and ongoing development work for potential next steps.

Positive

• Breast vaccine Phase 1 met primary endpoints with 74% immune responses
• Ovarian CAR-T lira-cel reporting positive survival data in ongoing Phase 1

Negative

• Both programs remain in Phase 1, indicating early-stage clinical risk
• No pivotal or late-stage efficacy or regulatory approvals reported to date

Argus Apr 6 session

+1.57% close to close Open Argus

Details

News Market Reaction – ANIX

In the Apr 6 session, ANIX gained 1.57%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement reinforces prior disclosures that Anixa’s breast cancer vaccine met Phase 1 endpoi...

Analysis

This announcement reinforces prior disclosures that Anixa’s breast cancer vaccine met Phase 1 endpoints with protocol-defined immune responses in 74% of participants and that its ovarian cancer CAR-T program has shown encouraging survival trends. The interview format extends the company’s outreach rather than adding new data. Investors may monitor upcoming Phase 2 planning, further CAR-T survival updates, cash trends around the reported $14.202M balance, and any use of the existing Form S-3 shelf or at-the-market facility.

Key Figures

Immune response rate: 74% of participants Trial phase: Phase 1 Patients treated: 13 patients +5 more

Immune response rate

74% of participants

Breast cancer vaccine Phase 1 trial primary immune response metric

Trial phase

Phase 1

Breast cancer vaccine clinical trial status at completion

Patients treated

13 patients

Ovarian cancer CAR-T Phase 1 dose-escalation trial per 10-Q

Net loss

$2.565M

Net loss attributable to common shareholders, quarter ended Jan 31, 2026

Prior-year net loss

$3.184M

Net loss same quarter a year earlier for comparison

R&D expenses

$1.102M

Research and development expenses for quarter ended Jan 31, 2026

Cash and investments

$14.202M

Cash, cash equivalents and short-term investments at Jan 31, 2026

Net tangible book value

$0.46 per share

Net tangible book value per share as of July 31, 2025 from S-3

Historical Context

5 past events · Latest: Apr 01

5 events

1. Apr 01

   Breast vaccine results

   24h Move

   +5.4%

   Final Phase 1 breast cancer vaccine data and Phase 2 manufacturing plans.

2. Mar 30

   CAR-T trial update

   24h Move

   -2.0%

   Announcement of upcoming ovarian cancer CAR-T trial presentation at SGO meeting.

3. Mar 12

   Investor podcast

   24h Move

   -2.7%

   CEO podcast discussing positive clinical data and company plans and finances.

4. Mar 09

   Patent allowance

   24h Move

   +4.6%

   Korean patent allowance expanding IP for breast cancer vaccine technology.

5. Mar 02

   Annual meeting notice

   24h Move

   -0.7%

   Annual meeting announcement with clinical and regulatory pipeline highlights.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

car-t therapy, phase 1 clinical trial, immunotherapy, primary endpoints, +1 more

5 terms

car-t therapy medical

"Anixa's ovarian cancer CAR-T therapy, lira-cel, is exhibiting positive survival data"

CAR-T therapy is a type of medical treatment that uses a patient's own immune cells, specially modified to better recognize and attack cancer cells. For investors, it represents a significant advancement in cancer care, with the potential to transform treatment options and generate substantial demand, making companies involved in its development and production potentially valuable in the healthcare industry.

phase 1 clinical trial medical

"recently completed a Phase 1 clinical trial where it met primary endpoints"

A phase 1 clinical trial is the first stage of testing a new drug or treatment in people, typically involving a small group to assess safety, how the body handles the treatment, and appropriate dosing. For investors, phase 1 results are an early risk check — like a test drive that can reveal fatal flaws or promising signals — and they often cause big changes in a drug’s perceived value and the company’s prospects.

immunotherapy medical

"advancing immunotherapy pipeline, including its breast cancer vaccine"

Treatment that uses or enhances the body’s immune system to detect and fight disease, most often cancers or chronic infections; think of it as training or arming the body’s own soldiers to find and destroy targets. It matters to investors because successful immunotherapies can lead to high-value drug approvals, recurring revenue from long-term treatments, and changes in competitive dynamics, while failures or safety issues in clinical trials can materially affect company valuations.

primary endpoints medical

"completed a Phase 1 clinical trial where it met primary endpoints"

Primary endpoints are the main, predefined measures a clinical trial uses to judge whether a treatment works, such as whether patients live longer or symptoms improve by a certain amount. They are the trial’s chief “scoreboard” subjects are measured against, and meeting or missing them strongly influences regulatory approval, market expectations and a drug’s commercial value—so investors watch them as a direct signal of risk and potential reward.

protocol-defined immune responses medical

"and generated protocol-defined immune responses in 74% of participants"

Pre-specified immune responses are the exact signs of immune activity a clinical trial team agrees to measure and count ahead of time—such as a certain antibody level or a rise in specific immune cells—listed in the study’s written plan. Investors care because these preset benchmarks act like a recipe’s success checklist: meeting them supports claims that a drug or vaccine works, which affects regulatory approval odds, market value and future sales potential.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN JOSE, Calif., April 6, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its Chairman and CEO, Dr. Amit Kumar, was recently featured in an interview on the Smart Money Circle program hosted by Adam Sarhan.

During the interview, Dr. Kumar discussed Anixa's innovative approach to cancer treatment and prevention, with a particular focus on the Company's advancing immunotherapy pipeline, including its breast cancer vaccine and ovarian cancer CAR-T therapy programs. Anixa's breast cancer vaccine recently completed a Phase 1 clinical trial where it met primary endpoints and generated protocol-defined immune responses in 74% of participants. In addition, Anixa's ovarian cancer CAR-T therapy, lira-cel, is exhibiting positive survival data in an ongoing Phase 1 clinical trial.

The full interview is available here: Smart Money Circle Interview.

About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of liraltagene autoleucel, or lira-cel, an ovarian cancer immunotherapy being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on LinkedIn, X, Facebook and YouTube.

Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-ceo-featured-on-smart-money-circle-interview-highlighting-advances-in-cancer-immunotherapy-programs-302734195.html

SOURCE Anixa Biosciences, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Anixa (ANIX) announce about its breast cancer vaccine on April 6, 2026?

The breast cancer vaccine completed a Phase 1 trial and met primary endpoints. According to the company, the trial generated protocol-defined immune responses in 74% of participants, indicating early immunogenicity evidence.

What did Anixa (ANIX) say about its ovarian CAR-T lira-cel on April 6, 2026?

Anixa reported that lira-cel is showing positive survival data in an ongoing Phase 1 trial. According to the company, these are early clinical signals that require further follow-up in later trials.

How might the Phase 1 results affect Anixa (ANIX) development timelines?

Phase 1 success may support progression to next-stage trials but does not set timelines. According to the company, ongoing development and additional data will determine the timing of later-stage studies.

Where was Anixa (ANIX) clinical progress discussed on April 6, 2026?

Anixa CEO Dr. Amit Kumar discussed pipeline advances on the Smart Money Circle interview. According to the company, the interview reviewed the breast vaccine and ovarian CAR-T clinical updates.

Does the April 6, 2026 update for Anixa (ANIX) include regulatory approvals?

No regulatory approvals were reported in the April 6, 2026 interview update. According to the company, the announcements described Phase 1 clinical results and ongoing trials only.